EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Is mild citrullinemia type I truly benign? a study of long-term clinical outcomes

Elif İşler-Soylu iD, Tuğçe Aras-Çöl iD, Hanım Babazade Aghakishili iD, Kağan Çalışgan iD, Tanyel Zubarioglu iD, Ertuğrul Kıykım iD, Mehmet Şerif Cansever iD, Ayşe Çiğdem Aktuğlu-Zeybek iD

Journal of Pediatric Endocrinology and Metabolism · 24.06.2026 · 39 (6) · 594-603

DOI: 10.1515/jpem-2025-0722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, online erschienen am 27.05.2026. Verfasst von Elif İşler-Soylu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Nutrition and Metabolism, İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, İstanbul, Türki…. Hauptthemen laut MEDLINE: Citrullinemia. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Citrullinemia type I (CTLN1), caused by variants in the ASS1 gene, is characterized by life-threatening neonatal hyperammonemia. The severity of CTLN1 correlates with residual enzyme function: nearly absent activity leads to severe neonatal presentations, while partial function results in milder forms. The increasing identification of patients with mild citrullinemia highlights the need for a deeper understanding of its natural history, genotype–phenotype correlations, and long-term management strategies. This study aims to characterize the clinical and molecular features of mild citrullinemia and explore its implications for long-term management.

Methods

We conducted a retrospective analysis of six pediatric patients diagnosed with mild CTLN1, examining their clinical presentations, biochemical parameters, and long-term outcomes.

Results

We present a case series of six patients (three males, three females; median age at presentation 0.5 years, median follow-up 8.5 years) identified through newborn screening (66.7 %), cascade testing (16.7 %), or symptomatic presentation (16.7 %). Consanguinity was present in half of the patients, including one sibling pair. None experienced metabolic decompensation. Baseline citrulline levels were mildly elevated (median 294 μmol/L) and ammonia levels ranged from mild to moderate (median 101 μmol/L; range 51–154 μmol/L). Arginine supplementation was administered to all patients at various stages without dietary protein restriction. Ammonia scavengers were used in three cases – two during the neonatal period and one at age 14 following neurological symptoms. Despite biochemical stability, half of patients had neurocognitive or psychiatric symptoms, including learning disabilities, obsessive compulsive disorder, attention deficit and hyperactivity disorder, and global developmental delay.

Conclusions

Our findings indicate that, despite its classification as “mild”, citrullinemia may involve underrecognized neurological risks, reflecting an incompletely understood pathophysiology. This underscores the importance of individualized treatment and long-term care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CitrullinemiaHumansFemaleMaleRetrospective StudiesInfantFollow-Up StudiesInfant, NewbornChild, PreschoolPrognosisChildCitrullineArgininosuccinate Synthase

Stichwörter der Autor:innen

citrullinemia type 1hypomorphic citrullinemiamild citrullinemiaurea cycle disorders

Substanzen

CitrullineArgininosuccinate Synthase

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Nutrition and Metabolism, İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, İstanbul, Türkiye.
  • Department of Medical Services and Techniques, Medical Laboratory Techniques Programme, Vocational School of Health Services, İstanbul University-Cerrahpaşa, İstanbul, Türkiye.
  • Department of Pediatrics, Metabolic Diseases Research Laboratory, İ stanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, İstanbul, Türkiye.

ORCID-Profile: Elif İşler-Soylu, Tuğçe Aras-Çöl, Hanım Babazade Aghakishili, Kağan Çalışgan, Tanyel Zubarioglu, Ertuğrul Kıykım, Mehmet Şerif Cansever, Ayşe Çiğdem Aktuğlu-Zeybek

Zitieren

APA

İşler-Soylu, E., Aras-Çöl, T., Babazade Aghakishili, H., Çalışgan, K., Zubarioglu, T., Kıykım, E., Cansever, M. Ş., & Aktuğlu-Zeybek, A. Ç. (2026). Is mild citrullinemia type I truly benign? a study of long-term clinical outcomes. Journal of Pediatric Endocrinology and Metabolism, 39(6), 594-603. https://doi.org/10.1515/jpem-2025-0722

Vancouver

İşler-Soylu E, Aras-Çöl T, Babazade Aghakishili H, Çalışgan K, Zubarioglu T, Kıykım E, et al. Is mild citrullinemia type I truly benign? a study of long-term clinical outcomes. Journal of Pediatric Endocrinology and Metabolism. 2026;39(6):594-603. doi:10.1515/jpem-2025-0722

BibTeX
@article{lerSoylu2026,
  author = {İşler-Soylu, Elif and Aras-Çöl, Tuğçe and Babazade Aghakishili, Hanım and Çalışgan, Kağan and Zubarioglu, Tanyel and Kıykım, Ertuğrul and Cansever, Mehmet Şerif and Aktuğlu-Zeybek, Ayşe Çiğdem},
  title = {Is mild citrullinemia type I truly benign? a study of long-term clinical outcomes},
  journal = {Journal of Pediatric Endocrinology and Metabolism},
  year = {2026},
  volume = {39},
  number = {6},
  pages = {594--603},
  doi = {10.1515/jpem-2025-0722}
}
Kostenlos starten →